A Case of Psoriasiform Eruption Triggered by Tumor Necrosis Factor-alpha Antagonist Therapy / 대한피부과학회지
Korean Journal of Dermatology
;
: 721-723, 2008.
Artículo
en Coreano
| WPRIM
| ID: wpr-44668
ABSTRACT
Tumor necrosis factor-alpha antagonists include monoclonal antibodies, infliximab, adalimumab, etanercept and golimumab. Clinical trials of these agents have shown that they are remarkably effective for psoriasis, but cutaneous adverse reactions of these agents including paradoxical aggravation of psoriasiform eruption have been also reported. We present a case of psoriasiform eruption triggered by golimumab therapy in a patient with rheumatoid arthritis. A 53-year-old woman presented with a skin lesion on the sole. She had been treated by golimumab every 4 weeks for rheumatoid arthritis from September 2006. 16 weeks after the treatment, she developed a erythematous and scaly patch on the sole. She had a history of palmoplantar pustulosis, but the skin lesions had not appeared for a long time, recurring when she started golimumab treatment. The skin lesion improved with topical steroid treatment, but as golimumab was re-administrated, the skin lesion exacerbated.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Artritis Reumatoide
/
Psoriasis
/
Piel
/
Inmunoglobulina G
/
Factor de Necrosis Tumoral alfa
/
Receptores del Factor de Necrosis Tumoral
/
Anticuerpos Monoclonales Humanizados
/
Adalimumab
/
Infliximab
/
Etanercept
Límite:
Femenino
/
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Dermatology
Año:
2008
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS